Drugs / CRB4101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05641181 | Nov 2022 → Apr 2023 | — | China Resources Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CRB4101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05641181 ↗ |
| Route | Oral | “Participants will receive a single oral dose of 100mg of CRB4101” NCT05641181 ↗ |